In the peer-reviewed study, Crescel’s biobotanical formula achieved a 54% reduction in facial redness, compared to 23% for the current prescription standard. Inflammatory lesions saw a 74% improvement, starkly contrasting with the 17% reduction observed in the control group. These results suggest a potential shift toward non-pharmaceutical interventions for a condition that currently affects roughly 400 million people globally.
In section Releases
Crescel Study Claims Biobotanical Cream Outperforms Standard Rosacea Care
A randomized, double-blind clinical trial published in the Journal of Cosmetic Dermatology indicates that Miami-based Crescel LLC’s proprietary microemulsion technology significantly reduces rosacea symptoms. The study reports that the company’s Skin Renewal Cream outperformed leading prescription standards in treating facial redness and inflammatory lesions without adverse side effects.
Peter J. Passalacqua, Jr., CEO of Crescel, noted that the data validates years of development aimed at providing effective alternatives to high-cost treatments. Dr. Roberta Shapiro, the company’s Chief Medical Officer and an Assistant Clinical Professor at Columbia University Medical Center, described the findings as a notable advancement, citing the cream’s healing capabilities and safety profile. The company intends to leverage these clinical outcomes to advocate for broader access to affordable, non-prescription-based skin health solutions.
Comments (0)
No comments yet. Be the first!